University of Minnesota Health – December 14, 2017
MnDRIVE Neuromodulation scholars Jerrold Vitek, Lauren Schrock, and Michael Park performed the first implant of an innovative Deep Brain Stimulation (DBS) device. Vitek also led the multi-site phase III clinical trial before the recent FDA approval of Boston Scientific’s Vercise system.
Unique among DBS devices, the Vercise system provides stimulation from eight individually controlled contact points for precise and flexible treatment.
Now, patients will have access to the device through standard medical care, without enrolling in a clinical trial, and it may be covered by their insurance.
See the links below for coverage from UMN Health News & Stories, OVPR’s Inquiry, and KMSTP-TV News.